Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
Phase 2
Completed
NCT03472586
| Condition | Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7 |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
|---|
| Status | Completed |
|---|
| Enrollment | 14 participants |
|---|
| Interventions | Ipilimumab, Nivolumab, Embolization Therapy |
|---|
| Start date | May 2, 2018 |
|---|
| Completion date | Dec 31, 2022 |
|---|
| Results posted | Nov 29, 2023 |
|---|
Summary
This phase II trial studies ipilimumab and nivolumab with immunoembolization in treating patients with uveal melanoma that has spread to the liver. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunoembolization may kill tumor cells due to loss of blood supply and develop an immune response against tumor cells. Giving ipilimumab and nivolumab with immunoembolization may work better in treating patients with uveal melanoma.
Hepatic Metastasis Stabilization Rate by Response Criteria (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
At the end of 4th treatment cycle (Day 84 +/- 3 days). Cycles are 21 days. · Participants
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 0 Participants |
|---|
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 0 Participants |
|---|
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 8 Participants |
|---|
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 5 Participants |
|---|
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 1 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.